Evidence map›Paper›PMID 40773142›Full record

ArticleCancer immunology, immunotherapy : CII2025

A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures.

Kyle J Hitscherich, Darryl Nousome, Aaron J Dinerman, Victoria Dulemba, Frank J Lowery, Naris Nilubol

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Kyle J HitscherichSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 112 Kendrick Place, Unit 34, Gaithersburg, Bethesda, MD, 20878, USA. kylehitsche@gmail.com.
Darryl NousomeCCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Aaron J DinermanSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 112 Kendrick Place, Unit 34, Gaithersburg, Bethesda, MD, 20878, USA.
Victoria DulembaSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 112 Kendrick Place, Unit 34, Gaithersburg, Bethesda, MD, 20878, USA.
Frank J LowerySurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 112 Kendrick Place, Unit 34, Gaithersburg, Bethesda, MD, 20878, USA.
Naris NilubolEndocrine Surgery Section, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD, USA. naris.nilubol@nih.gov.

Funding

Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NILUBOL, NARIS · 2010 to 2025
$16.6M
Intramural NIH HHS ZIA BC011286NIH HHS ZIA BC 011286
6 · The paper itself

Abstract

Efforts to understand the tumor microenvironment through basic science research and the cancer genome atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL). However, no pan-cancer analysis has been conducted to compare the prognostic performance of these signatures using overall survival (OS) or progression-free interval (PFI) as endpoints. We compiled a library of 146 TIL-immune signatures and evaluated gene signature score correlation with OS and PFI for 9,961 available TCGA samples across 33 tumor types. Zhang CD8 TCS demonstrated higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape; however, variability was seen across cancer types and germ cell origin. Cluster analysis compiled a group of six signatures (Oh.Cd8.MAIT, Grog.8KLRB1, Oh.TIL_CD4.GZMK, Grog.CD4.TCF7, Oh.CD8.RPL, Grog.CD4.RPL32) whose association with OS and PFI could potentially be conserved across multiple neoplasms.

Indexed as

Biomarkers, TumorLymphocytes, Tumor-InfiltratingNeoplasmsTranscriptomeGene Expression ProfilingHumansPrognosisTumor MicroenvironmentBiomarkers, TumorCancerImmunotherapySingle cell sequencingTumor-infiltrating lymphocytesTumor microenvironment

Identifiers

PMID40773142
PMCPMC12332167

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.